title: Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
abstract: BACKGROUND
  Incorporating mediastinoscopy (MS) into the PET-based strategy for non-small cell lung carcinoma (NSCLC) patients might be cost-effective because MS can allow unnecessary thoracotomies to be avoided. The objective of our study was to assess the cost-effectiveness of incorporating MS into a PET strategy for NSCLC patients.
  
  
  METHODS
  To determine life expectancy (LE), quality adjusted life years (QALY), and the incremental cost-effectiveness ratio (ICER), a decision-tree sensitivity analysis was designed for histopathologically confirmed NSCLC patients with M0 disease, based on the three competing strategies of chest CT only vs. PET + CT vs. PET + CT + MS. A simulation of 1000 NSCLC patients was created using baselines of other relevant variables in regard to sensitivity, specificity, mortality, LE, utilities and cost from published data. One-way sensitivity analyses were performed to determine the influences of mediastinal metastasis prevalence on LE, QALY and ICER.
  
  
  RESULTS
  The LE and QALY per patient in the CT only strategy, PET + CT strategy and PET + CT + MS strategy were 4.79 and 4.35, 5.33 and 4.93 and 5.68 and 5.33 years, respectively, with a 20% prevalence of mediastinal metastasis. The ICERs were 906.6 yen x 10(3) (7555 US dollars)/QALY/patient at a 20% mediastinal metastasis prevalence, and 2194 yen x 10(3) (18,282 US dollars)/QALY/patient at a 50% prevalence, but exceeded 5280 yen x 10(3) (44,000 US dollars)/QALY/ patient at 80%.
  
  
  CONCLUSIONS
  Our study quantitatively showed the CT + PET + MS strategy in place of the PET + CT strategy in managing NSCLC patients to be cost-effective. MS should be incorporated into the PET + CT strategy for NSCLC patients except in those highly suspected of having mediastinal disease on chest CT or PET.
authors.affiliation: Department of Radiology, National Defense Medical College, Tokorozawa, Japan.
authors.forename: Katsumi
authors.initials: K
authors.lastname: Hayashi
authors.forename: Katsumi
authors.initials: K
authors.lastname: Abe
authors.forename: Fuzuki
authors.initials: F
authors.lastname: Yano
authors.forename: Sadahiro
authors.initials: S
authors.lastname: Watanabe
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kosuda
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D019788:Fluorodeoxyglucose F18 / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology; D008207:Lymphatic Metastasis; D008481:Mediastinoscopy / Q000191:economics* / Q000706:statistics & numerical data; D008482:Mediastinum / Q000000981:diagnostic imaging / Q000473:pathology; D018803:Models, Economic; D049268:Positron-Emission Tomography / Q000191:economics* / Q000706:statistics & numerical data; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000191:economics / Q000706:statistics & numerical data
chemical_list: D019788:Fluorodeoxyglucose F18